Sean Boyd

Dr. Sean Boyd


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in Anaesthesia
Verified
Journal Article
Open access
SBSean Boyd
Sean Boyd
CMCiara J. Murphy
Ciara J. Murphy
LSLindi Snyman
Lindi Snyman
Summary: Introduction: Flexible bronchoscopes have become essential in the operating theatre environment and in critical care. This narrative review compared single‐use and reusable flexible bronchoscopes with a focus on safety, efficacy, cost‐effectiveness and environmental impact. Methods: We searched MEDLINE, Embase and PubMed databases for studies related to flexible bronchoscopes for airway management or use in critical care. Human or animal studies of any design assessing single‐use and reusable flexible bronchoscopes were included and qualitatively synthesised. We also searched manufacturer websites for relevant data. Results: We included 52 studies and data from six manufacturer websites. There was mixed evidence for safety, and data on usability also showed significant heterogeneity, with different parameters, manufacturers and models examined. Neither single‐use nor reusable flexible bronchoscopes appeared convincingly superior to the other for safety or usability. Cost analyses showed that the rate of use of flexible bronchoscopes per year, along with several other factors, affects cost‐effectiveness for each institution, though the risk of cross‐contamination is an advantage of single‐use devices. However, sufficient evidence on the rate of bronchoscopy‐induced infection in the operating theatre and critical care environment is lacking. Due to the risk of cross‐contamination, single‐use flexible bronchoscopes must be sterilised or incinerated after use, and completely recyclable single‐use models are not currently available. Conclusions: Further research is required on safety, usability and life cycle assessment in the operating theatre and critical care environment, as well as on the rate of bronchoscopy‐induced infection. Future comparative studies, including new manufacturers and designs, may lend further insights.

7 January 2021 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
SBSean Boyd
Sean Boyd
Ignacio Martin-LoechesIgnacio Martin-Loeches
Ignacio Martin-Loeches

8 June 2022 in Medical Sciences
Verified
Journal Article
Open access
PDF file
SBSean Boyd
Sean Boyd
KLKai Sheng Loh
Kai Sheng Loh
JLJessie Lynch
Jessie Lynch
DADhari Alrashed
Dhari Alrashed
SMSaad Muzzammil
Saad Muzzammil
Ignacio Martin-LoechesIgnacio Martin-Loeches
Ignacio Martin-Loeches
The rate of venous thromboembolism in COVID-19 patients has been reported to be 30% (deep vein thrombosis 20% and pulmonary embolism 18%). This has been shown to be higher in COVID-19 patients admitted to the ICU. Prophylactic anticoagulation may be sufficient at ward level, but not in intensive care. A retrospective chart review was undertaken in a large university hospital. The review included 276 patients from COVID-19 Wave 1, COVID-19 Wave 2, influenza, and community-acquired pneumonia groups. The timeframe included patients admitted between 23 February 2014 and 12 May 2021. Clinical characteristics, outcomes, blood results, rates of venous thromboembolism, and anticoagulation status were recorded. The incidence of venous thromboembolism in COVID-19 Wave 1, COVID-19 Wave 2, influenza, and community-acquired pneumonia was 10.91%, 13.69%, 13.33%, and 6.81%, respectively (p = 0.481). The incidence of pulmonary embolism was 7.27%, 10.95%, 3.33%, and 5.68%, respectively (p = 0.350). The incidence of deep vein thrombosis was 5.45%, 5.48%, 10.00%, and 1.14%, respectively (p = 0.117). Although most patients were prophylactically anticoagulated, venous thromboembolism still occurred. Venous thromboembolism remains an important differential to consider in critically ill COVID-19 patients. The current literature does not advise therapeutic anticoagulation for thromboprophylaxis in the ICU.

7 May 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
SBSean Boyd
Sean Boyd
KLKai Sheng Loh
Kai Sheng Loh
JLJessie Lynch
Jessie Lynch
DADhari Alrashed
Dhari Alrashed
SMSaad Muzzammil
Saad Muzzammil
Ignacio Martin-LoechesIgnacio Martin-Loeches
Ignacio Martin-Loeches
Due to multiple risk factors, the rate of ventilator-associated pneumonia in critically ill COVID-19 patients has been reported in a range of 7.6% to 86%. The rate of invasive pulmonary aspergillosis in this cohort has been reported at 4% to 30%. We undertook a retrospective chart review of 276 patients who were admitted to intensive care in a large university hospital. The period studied included patients from 23 February 2014 to 12 May 2021. Four groups were collected: COVID-19 Wave 1, COVID-19 Wave 2, influenza, and community-acquired pneumonia. Clinical characteristics, outcomes, and microbiological cultures were recorded. The incidence of ventilator-associated pneumonia in COVID-19 Wave 1, COVID-19 Wave 2, influenza, and community-acquired pneumonia was 5.45%, 27.40%, 16.67%, and 3.41%, respectively (p < 0.001). The rate of invasive pulmonary aspergillosis was 0%, 9.59%, 13.33%, and 6.82%, respectively (p < 0.001). A significantly elevated rate of ventilator-associated pneumonia and invasive pulmonary aspergillosis was noted in the second wave of COVID-19 when compared to the first. This was accompanied by an increase in the mortality rate. Increased steroid use was an independent risk factor for ventilator-associated pneumonia and invasive pulmonary aspergillosis across all four groups. Despite an increased understanding of this disease, no clinical trials have shown any promising therapeutic options at present.

8 January 2021 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
SBSean Boyd
Sean Boyd
Ignacio Martin-LoechesIgnacio Martin-Loeches
Ignacio Martin-Loeches

1 August 2019 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
SBSean Boyd
Sean Boyd
AOAnna D. O’cOnnor
Anna D. O’cOnnor
MHMaebh A. Horan
Maebh A. Horan
PDPat Dicker
Pat Dicker
CMCatherine Manning
Catherine Manning
BBB.M. Byrne
B.M. Byrne